Pathophysiology of Rebound Intracranial Hypertension
Article information
INTRODUCTION
Rebound intracranial hypertension (RIH) is an overlooked phenomenon in intensive care medicine. This is characterized by a secondary rise in intracranial pressure (ICP) after an initial period of ICP control (Fig. 1). Some of the common causes include withdrawal of osmotherapy, cerebrospinal fluid drainage limitation, or decompressive craniectomy effect, hence resulting in clinical deterioration.
Pathophysiological basis of rebound intracranial hypertension.
PATHOPHYSIOLOGICAL OVERVIEW
Rebound intracranial hypertension is a secondary rise in ICP following a period of successful medical or surgical control of intracranial hypertension1). It typically emerges during recovery or while tapering therapies such as osmotic agents, cerebrospinal fluid (CSF) drainage, or after decompressive surgery1,2). This is in contrast to primary intracranial hypertension, which results directly from the underlying acute insult, such as trauma, hemorrhage, or ischemia. It remains iatrogenic in nature and is unable to maintain a stable intracranial environment once the effect is reduced3,4).
According to illustrations in Fig. 1, the pathophysiological cascade leading to rebound intracranial hypertension initiates with the primary brain insult, beginning with edema formation through mechanisms of brain swelling, impaired lymphatic drainage, altered CSF circulation, and venous outflow obstruction. These processes together raise intracranial pressure (ICP), initiating transient stabilization through compensatory responses including CSF displacement, venous blood volume reduction, autoregulatory vasoconstriction, and cellular osmotic buffering. However, as depicted in the “Rebound Mechanisms” phase of Fig. 1, exhaustion of these compensatory processes leads to a secondary rise of ICP. This is characterized by impaired autoregulation, worsening edema, venous congestion, and loss of intracranial compliance. The mechanistic progression explains why RIH manifests after initial ICP control and highlights its potential to produce cerebral ischemia, brainstem compression, herniation syndromes, and Cushing’s triad, as shown in the downstream impact section of Fig. 1.
The exact incidence is unknown, but rebound intracranial hypertension is increasingly recognized in critical care settings, most probably in patients undergoing aggressive ICP management1,2). Its detection is often difficult because clinical deterioration may be attributed to the primary disease rather than to rebound physiology. If not recognized at the correct time, it can lead to secondary brain injury, herniation, and poor neurological outcomes, emphasizing the importance of careful monitoring, gradual weaning of therapies, and individualized management strategies3-5).
DISCONTINUATION OF MANNITOL OR HYPERTONIC SALINE
Hyperosmolar agents such as mannitol and hypertonic saline are the most important aspects in the management of elevated ICP as they lead to an osmotic gradient that facilitates the movement of water from the brain parenchyma to the intravascular compartment6-8).
When these agents are withdrawn too rapidly—particularly after prolonged administration—the osmotic gradient can reverse, causing a reaccumulation of water within the brain tissue. This effect is most pronounced in regions with a disrupted blood-brain barrier, resulting in RIH9-11).
This rebound physiology is in line with the mechanisms depicted in Fig. 1, particularly the component labelled “BBB Disruption – Fluid Leak,” where withdrawal of hyperosmolar therapy unmasks increased blood–brain barrier permeability, allowing a renewed influx of water into the parenchyma. Continuing the process, the figure's “Cellular Osmotic Adjustment” pathway illustrates how astrocytes gradually accumulate osmolytes during prolonged osmotherapy; once therapy is discontinued suddenly, the retained intracellular osmolytes pull the water back into the brain, producing a rebound rise in ICP. Both of the above components together, these Fig. 1 elements emphasize that the pathophysiology of rebound intracranial hypertension is not just a passive reversal of osmotic gradients but a structured, mechanistically predictable failure of osmotic and vascular compensatory systems.
Patients with renal dysfunction, systemic inflammation, or pre-existing blood-brain barrier injury are especially susceptible due to altered osmotic homeostasis4,5).
AFTER CLOSURE OR CLAMPING OF AN EXTERNAL VENTRICULAR DRAIN
External ventricular drains are commonly used to control ICP by diverting cerebrospinal fluid. Cerebrospinal accumulation and rebound rise in ICP are a result of sudden discontinuation or premature clamping, without gradual tapering of intracranial pressure1-3).
This is common in clinical conditions of subarachnoid hemorrhage, obstructive hydrocephalus, or impaired CSF reabsorption, where normal CSF dynamics are compromised12).
In case of failure of EVD weaning trial, it often results in a gradual rise of ICP with neurological deterioration13).
Recent consensus-based guidelines advocate for stepwise reduction of hyperosmolar therapy and controlled EVD weaning or trial of clamping the external ventricular device with optimal output. Multimodal monitoring of ICP and brain tissue oxygenation to minimize rebound events and optimize neurological outcomes should also be taken into account14).
FOLLOWING DECOMPRESSIVE SURGERY OR ONCE CEREBRAL EDEMA HAS BEEN RESOLVED
Decompressive craniectomy and other modes of surgical decompression effectively lower ICP by allowing expansion of swollen or congested brain tissue and restoring intracranial compliance. However, compensatory alterations in cerebral hemodynamics, venous drainage, and cerebrospinal fluid flow after decompression—if not adequately regulated—can paradoxically trigger a secondary rise in ICP4,5).
As edema subsides, evolving changes in compartmental compliance and intracranial elastance may lead to delayed shifts in ICP, producing a rebound pattern of intracranial hypertension. These events are frequently associated during the recovery phase with disrupted autoregulation, impaired cerebrospinal fluid absorption, or increased venous outflow resistance9,10).
After cranioplasty, rebound cranial hypertension has been reported, due to sudden restoration of the rigid cranial vault, which causes a change in the CSF hydrodynamics and venous return, decreasing the intracranial compliance11-13). Along with this, postoperative monitoring of ICP and gradual adjustment of pressure targets in cerebral perfusion are recommended to reduce secondary intracranial pressure surges14).
Recent evidence and consensus statements emphasize the importance of stepwise management, ensuring hemodynamic stability and multimodal monitoring—including ICP and brain oxygenation—during decompressive surgery and the cranioplasty phase to prevent rebound phenomena12,14).
CLINICAL IMPLICATIONS OF REBOUND INTRACRANIAL HYPERTENSION
The development of RIH presents significant diagnostic and therapeutic challenges, consistently associated with a variety of adverse clinical outcomes. Early recognition and prompt actions are important, as unrecognized or not treated adequately, this leads to a rise in ICP, posing neurological decompensation and poor outcomes12,15).
Neurological Deterioration
The most critical manifestation of rebound intracranial hypertension is acute neurological decline, with a decrease in the level of consciousness or new focal neurological deficits4,5).
Patients frequently exhibit restlessness, drowsiness, or disorientation; however, radiological evaluation demonstrates no new abnormalities. In critically or sedated patients, sentinel signs—such as unexplained agitation, altered pupillary reactions, or decerebrate posturing—may serve as early indicators of an increase in ICP6,7).
Cushing's Triad
An increase in intracranial hypertension and decline in cerebral perfusion pressure may result in the Cushing reflex- systemic hypertension, bradycardia, and irregular respiration8,9).
These signs indicate brainstem compression and impending herniation. Thus, an immediate clinical reassessment and urgent therapeutic measures are of utmost priority.
Reduction or discontinuation of hyperosmolar therapy, particularly after mannitol or hypertonic saline withdrawal, can also be one of the causes in this case10,11,14).
Increased Risk of Herniation
Undetected or poorly treated cases of rebound intracranial hypertension can precipitate transtentorial or uncal herniation16,17) with clinical manifestations of pupillary dilation, hemiparesis, coma, and ultimately brainstem failures.
As herniation frequently happens in patients who were previously thought to be stable, this condition may be harmful; it can be mistakenly attributed to worsening or complicating variables such as drowsiness, infection, or metabolic disorders18).
Hence, continuous ICP and neurological monitoring during weaning of therapy or postoperative recovery is important to avoid catastrophic outcomes.
Delayed Recovery or Poor Outcome
Although herniation may not exist, persistent or intermittent ICP elevation can be hazardous to cerebral perfusion, exacerbate metabolic stress, and be an obstacle to neurological recovery19).
Chronic cases of rebound intracranial hypertension can cause prolonged intensive care stay, extended mechanical ventilation, or the need for reinstitution of intensive therapies, thereby increasing both morbidity and healthcare costs. It can also cause impaired functional outcomes and delayed neurocognitive rehabilitation in patients recovering from severe traumatic brain injury or decompressive procedures13,15,20).
CONCLUSIONS
Rebound intracranial hypertension remains a clinically significant complication in neurocritical care. The importance of gradual weaning of ICP-lowering therapies, vigilant monitoring, and individualized management protocols should be taken into account. Multimodal monitoring and stepwise ICP control strategies should be brought into existence in the standard practice of management to reduce secondary injury and optimize neurological recovery.
Notes
Ethics statement
None.
Author contributions
Conceptualization: PSB, CRL, WFP, TJ. Formal analysis: CRL, AA, LRMS. Methodology: CRL. Data curation: AA. Project administration: WFP, LRMS, TJ. Writing - original draft: PSB, WFP, LRMS, TJ. Writing - review & editing: PSB, TJ.
Conflict of interest
There are no conflicts of interest to disclose.
Funding
This study did not receive any funding or financial support.
Data availability
None.
Acknowledgments
None.